Degenerescence programmee de maladies musculaires: aspects moleculaires et previsions therapeutiques. [Mechanisms leading to muscle degeneration: molecular mechanisms and therapeutical forecasts]

Détails

ID Serval
serval:BIB_2A4E808CFB3C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Degenerescence programmee de maladies musculaires: aspects moleculaires et previsions therapeutiques. [Mechanisms leading to muscle degeneration: molecular mechanisms and therapeutical forecasts]
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Kuntzer  T., Bader  C. R., Sinnreich  M.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
05/2006
Peer-reviewed
Oui
Volume
2
Numéro
64
Pages
1174-7
Notes
English Abstract Journal Article Review --- Old month value: May 3
Résumé
In inclusion body myositis (IBM), there is muscular amyloidogenesis and inflammation. A related disorder is due to alterations in the ubiquitin pathway involving the valsolin-containing protein leading to IBM, dementia and Paget's disease. Alteration in the dystrophin glycoprotein complex leads to several muscular dystrophies (MD), and the pathogenesis of dystrophin related MD as well as certain limb girdle MD are discussed. Therapeutic strategies involving inhibition of proteolytic cascades as well as inhibition of a negative regulator of muscle growth (myostatin) are briefly introduced. Finally, molecular aspects of the most common form of adult myopathy, myotonic MD, are discussed. This disease is caused by an aberrant splicing mechanism and interference thereof may be useful in designing therapeutic strategies.
Mots-clé
Humans Muscular Dystrophies/*drug therapy/*genetics Myositis, Inclusion Body/*drug therapy/*genetics
Pubmed
Création de la notice
25/01/2008 13:43
Dernière modification de la notice
20/08/2019 14:09
Données d'usage